Nilogen Oncosystems

Nilogen Oncosystems is a private, pre-revenue biotechnology company providing a proprietary translational research platform for immuno-oncology. Its patented 3D-EXplore technology creates 'tumoroids' from minimally processed fresh patient tissue, preserving the intact tumor microenvironment (TME) and heterogeneity to better predict clinical drug response. The company offers this as a service to biopharma clients for testing cell therapies, oncolytic viruses, antibodies, and chemotherapies, and is also conducting its own clinical trial to validate the platform's predictive power.

Patented 3D-EXplore tumoroid technology. Creates 3D micro-tumor fragments ('tumoroids') from minimally processed fresh human tumor tissue, preserving the intact tumor microenvironment (TME) and heterogeneity. Integrated with multi-omics analytics, high-content imaging, flow cytometry, and AI-driven bioinformatics.

Nilogen competes in the broad market for preclinical cancer models, which includes traditional 2D cell lines, patient-derived xenografts (PDXs), and other 3D systems like organoids and spheroids. Its key differentiation is the emphasis on minimal processing to preserve the native TME, unlike organoids which are often expanded. Competitors include other specialized CROs offering complex in vitro models and larger CROs with internal 3D model capabilities.